Abstract
Provisional patent specification for USPTO filing. Discloses computational methods for drug repurposing in multiple sclerosis (MS) using single-cell RNA sequencing of cerebrospinal fluid (CSF) from 6 MS patients and 6 IIH neurological controls, variational autoencoder-based dimensionality reduction (scVI), Leiden clustering, Wilcoxon differential expression (MS vs IIH primary, plus T cell, B cell, monocyte, and pro-MS cluster subsets), and LINCS L1000 transcriptomic reversal scoring. Application to GSE138266 across 26 independent Enrichr queries identified 236 NOVEL_ALL candidates. Top candidates: SA-440832 (priority 124,503), AMG-837 (TRPV1 antagonist, 76,398), R-547 (CDK inhibitor, 61,143), RG-7388 (MDM2 inhibitor, 60,244), SAR405838 (MDM2 inhibitor, 59,365), LXR-623 (LXR agonist, 55,577), IPI-145/duvelisib (PI3Kδ/γ inhibitor, 52,368). IPI-145 implicates dual PI3K inhibition as a novel intrathecal MS therapeutic strategy. LXR-623 addresses both neuroinflammation suppression and remyelination promotion. MDM2 inhibitors extend cross-disease p53-MDM2 axis findings to three independent tissues. Inventor: Glen Charles Ritschel, Ritschel Research, Tega Cay, SC. Micro-entity filing.